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ABSTRACT
Objective: The aim of this study was to compare the outcome of intra-lesional autologous bone marrow concentrate (BMC) and equine 
derived demineralized bone matrix (EDDBM) injections with methylprednisolone acetate injections in patients with simple bone cyst. 
Methods: Clinical records and radiographs of 53 consecutive patients (37 females,and 16 males; mean age: 10.6±1.53 years) treated 
between 2006 and 2016 were retrospectively reviewed. Healing was assessed by an independent radiologist according to Neer scor-
ing system. Functional outcome was assessed with the Activity Scale for Kids (ASK). Thirty-four cysts were in the humerus, 13 in 
the femur and 6 in other locations. Twenty-nine patients were included in Steroid Group and treated with 3 cycles of injections of 
methylprednisolone acetate, while 24 patients were treated with injection of autologous bone marrow concentrate and equine derived 
demineralized bone matrix (BMC+ EDDBM Group). The two groups were homogenous for the mean age, sex distribution, cysts 
location and their clinical presentation. 
Results: At a minimum follow-up of 24 months, success rate (Neer/Cole score 3 and 4) was higher in EDDBM+BMC group (83.3% vs 
58.6%; p=0.047). Female patients had higher healing rates in both groups (p=0.002). No association was found between healing and 
age (p=0.839), cyst activity (p=0.599), cyst localization (p=0.099) and clinical presentation (p=0.207). BMC+EDDBM group showed 
higher ASK score (p=0.0007). 
Conclusion: Treatment with BMC+EDDBM injections may provide better results with a single procedure than 3 methylprednisolone 
acetate injections and represent an interesting alternative for the treatment of unicameral bone cysts.
Level of Evidence: Level III, Therapeutic Study
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Simple bone cysts are benign, fluid-containing, and 
usually expanding lesions that affect children be-
fore skeletal maturity.
Virchow first described these lesions in 1876 (1), 
but Heineke et al. gave a more detailed descrip-
tion of their radiographic aspect in 1903 (2). In 
1942, Jaffe et al. first used the term bone cysts 
and defined these lesions as bone dysplasia with 
cystic aspectsmostly in the metaphysis of long 
bones (3).
They represent 3% of all bone lesions and are more 
common in long bones. Simple bone cysts (SBCs) 
could show up with or without pain, and often are 
diagnosed as an incidental finding on a radiograph. 
Furthermore, SBCs could be complicated by patho-
logical fractures (4).
Even if SBCs might be asymptomatic and regress 
spontaneously, surgical treatment is often advised 
(4-6). Cortex-thinning results in focal weakening 
and the bone is thus at risk for pathologic fractures 
(7, 8). The main goals of treatment, therefore, are 
to decrease the risk of fracture and promote cyst 
healing (8, 9).
Nowadays, there are many treatment options such 
as intra-cystic injections of steroids or bone sub-
stitutes, mechanical disruption of the cystic wall, 
decompression, nailing, or combined treatments 
(10, 11). Scaglietti et al. proposed repeated percuta-
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neous injections of corticosteroids in 1979 (12). Due to low mor-
bidity, technical simplicity, and a high healing rate reported by 
the author (90%), this treatment has been widely used (13-16). 
Subsequent studies, however, reported a lower healing rate (41–
63% after the first injection) (17, 18). Sung et al. and colleagues 
reported a success rate of 16% after the first steroid injection and 
24% after repeated procedures (19). The injection of autologous 
bone marrow (BM) alone or in combination with demineralized 
bone matrix (DBM) was proposed as an alternative to steroids for 
treating SBCs. BM should provide osteoprogenitor cells and DBM 
could stimulate new bone formation thanks to its osteoconductive 
properties (20-28).
We hypothesized that intralesional injections of bone marrow con-
centrate, associated with equine-derived demineralized bone ma-
trix (EDDBM+BMC), could be effective in the treatment of SBCs.
This study, therefore, aims to compare the outcomes of intralesion-
al injections of EDDBM+BMC versus methylprednisolone acetate 
injections regarding the healing rate in the surgical treatment of 
SBCs. We furthermore aim to highlight whether the healing rate is 
influenced by the age and gender of the patients, and activity and 
localization of the cystic lesions.
Materials and Methods
The Institutional Review Board (IRB) of the Gaetano Pini Ortho-
pedic Institute approved the execution of this retrospective study 
(IRB No. 2019-0027).Written informed consent was obtained 
from the parents of the patients who participated in this study.
Patients affected by SBC and treated at our institute from 2006 to 
2016 were retrospectively reviewed. From this cohort, the crite-
ria for participants included in the study were: SBC regardless of 
anatomic location confirmed by radiological features and cyto-
pathological examination of the intra-cystic fluid with a high risk 
of fracture according to anatomical location, thickness of the cyst 
wall (<2 mm) (8) or sport participation (sport participation en-
hances the probability of trauma), patients with a clinical presen-
tation of spontaneous pain or incidental radiological findings of 
pathological fractures, patients having a persistence of SBC after 
at least 12 months of conservative treatment for pathological frac-
tures, and patients with minimum follow up of 24 months. As-
ymptomatic SBCs that were detected incidentally and cysts that do 
not cause a risk for pathological fractures with a thickness of cyst 
wall greater than 2 mm were excluded from the study. Fifty-three 
consecutive patients (37 females, 16 males) met the criteria to be 
included in the cohort. Informed consent was obtained from the 
patients who were included in this study.
Clinical presentation was a pathologic fracture of the cyst wall in 
36 patients, local pain in 12 patients, and incidental radiographic 
findings in the remaining five patients. Thirty-four (34) cysts were 
in the humerus, thirteen (13) in the femur, and six (6) in other 
localizations.
Twenty-nine (29) patients were treated with repeated injections of 
methylprednisolone (Steroids Group (SG)) and 24 with an injec-
tion of autologous EDDBM+BMC (EDDBM+BMC Group).
There were 21 females and 8 males in the Steroid Group (mean age 
at treatment is 10.7 years; range 9 to 15 years) and 16 females and 
8 males in the EDDBM+BMC Group (mean age at treatment is 
10.5 years; range 9 to 14 years). The 24 months of minimum follow 
up started from the last cycle of treatment for both groups. Mean 
follow up for the SG is 79.3 months (range 24 to 120 months) while 
mean follow up for the EDDBM+BMC Group is 46.5 months 
(Range 24 to 60 months).
In the SG, 17 lesions were humeral, 8 femoral, and 4 in other lo-
cations. In the EDDBM+BMC Group, 17 lesions were humeral, 
5 femoral, and 2 in other locations. We classified SBCs as active 
when they were within 1 cm of the physis (Table 1).
In the SG, patients undergo general anesthesia. Two needles are 
percutaneously inserted proximally and distally inside the cyst 
under fluoroscopic guidance. Through the first needle, the cyst 
fluid content is aspirated and delivered to histological examina-
tion, then a saline solution is injected through the cyst to perform 
washing. Afterward, a steroid injection, based on the estimated 
cyst volume, calculated on two-plane radiographs of the lesion site 
(6 x length x width x depth), is performed with methylpredniso-
lone acetate. The mean cyst volume in this group was 25cc (15cc 
to 40cc). No curettage was performed in between the washing and 
steroid injections steps. Patients of the SG underwent a cycle of 
three methylprednisolone injections at three-month intervals. 
In the EDDBM+BMC Group, the surgical procedure was done in 
two phases. In the first phase, 60 mL BM is aspirated from the iliac 
wing through a single puncture with a Jamshidi needle inserted 
in zones 1, 2, or 3, according to Hernigou et al. (29, 30). It was 
then linked to a 30cc syringe, pre-filled with a solution of 0.5 mL 
heparin in 5mL of saline solution. The first syringe is filled with 
10mL of BM, mixed with anticoagulant by manual shaking, and 
then another 10 mL of BM is aspirated. At each step of aspiration, 
the Jamshidi needle is rotated 90° and retracted 0.5–1cm to collect 
a greater number of staminal cells, draining those more adherent 
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• There’s no standardized treatment for the management of unicam-
eral simple bone cysts in literature. No option has shown striking 
results.
• Equine derived demineralized bone matrix intralesional injection 
showed better healing rate and, consequently better functional out-
comes than methylprednisolone acetate.
• Equine derived demineralized bone matrix showed to be an effective 
and safe treatment option for orthopedic surgeon in the manage-
ment of this pathology.
M A I N  P O I N T S
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Table 1. Resume of clinical and radiological features of patients involved in the study. Group A=Steroid Group; Group 
B=EDDBM+BMC group; M=male; F=Female; R=Right; L=Left; Y=Yes; N=No; ASK=activity scale for kids. Neer grade 1 or 2 after 
procedure was taken as treatment failure and grade 3 or 4 as treatment success. ASK score > 90 was graded as excellent, score ranging 
between 80 and 89 as acceptable and score lower than 80 as not acceptable. In Group A each treatment cycle consists of three injections 
while in Group B it consists of one injection
EDDBM: Equine Derived Demineralized Bone Matrix; BMC: Bone Marrow Concentrate
to the cancellous bone. This alternating pattern of aspiration was 
continued until 60 mL of BMwas collected. 
The aspirated BM was then filtered directly in the operating room 
through a dedicated kit (IOR-G1, Novagenit, Italy). The sample 
was concentrated in a cell separator (Re-Q 60) at 3200 rpm for 
12 minutes obtaining 10 mL of BM, rich in nucleated cells such 
as stem cells, monocytes, lymphocytes, and BM resident cells and 
poor in red cells (>8.86× 106 of Mono Nucleated Cells) (Figure 
1). In the second phase, under fluoroscopy guidance, two needles 
are inserted into the cyst to drain the intra-cystic fluid, deliver a 
sample for histological examination and perform cyst washing. 
Afterward, one needle is removed and the concentrated BM mixed 
with 5 to 10mL of EDDBM paste (ACTIVAGEN, Bioteck, Italy), 
according to cyst volume, is injected under pressure by the second 
needle.
In both groups, the overall procedure time ranged from 30 to 45 
minutes. All patients underwent a cycle of three steroid injections 
or one EDDBM+BMC injection. If the cyst persisted by the 12th 
month of follow up, a second cycle of steroid injections or EDDB-
M+BMC was performed.
All patients were discharged one or two days after surgery. Free 
movements were allowed after 7–15 days. Sports activities were 
forbidden for two to three months.
Patients in both groups were followed in the outpatient clinic to 
assess cyst healing and clinical results at 3, 6, 12, and 24 months 
after surgery.
We obtained radiographs of the cyst at each control and they were 
evaluated by an independent radiologist using the Neer scor-
ing system modified by Cole (18) as grade 1, cyst clearly visible; 
grade 2, cyst visible but multilocular and opaque; grade 3, scle-
rosis around or within a partially visible cyst; grade 4, complete 
obliteration of the cyst. Grade 1 and grade 2 results are considered 
failures while grades 3 and 4 are considered successes. 
The ASK is a 30-item child self-report questionnaire about phys-
ical activity with excellent reliability (ICC=0.97). It was designed 
for children of 5 to 15 years of age affected by musculoskeletal dis-
orders (31, 32).
The questionnaire was sent to patients at the two-year follow up.
An independent statistician performed the statistical analysis. 
Data were expressed as frequencies, percentages, means, and SDs. 
Associations between the healing rate and treatment group, age, 
gender, activity, and localization of the cysts were explored using 
the chi-square test. The student t-test was used to assess the differ-
ences in AKS between the two groups. Statistical significance was 
set at p<0.05.
Results
Between the two study groups there was no significant difference 
in the age (p=0.599), gender (p=0.659), location (p=0.357), ac-
tivity (p=0.686), and clinical presentation of the cysts (p=0.409) 
(Table 2).
An additional cycle of injections was performed in seven (7) pa-
tients in the SG and six (6) patients in the EDDBM+BMC Group 
who presented with a cyst stage 1 and 2 according to the Neer clas-
sification, modified by Cole, 12 months after the first cycle of treat-
ment. Persistent small cystic lesions (<1 cm3), despite their Neer 
classification that did not make the cyst wall thinner than 2 mm, 
were not treated with an additional cycle of injections.
D’Amato et al. / Acta Orthop Traumatol Turc 2020; 54(1): 49-58 
52
Figure 1. a-c. Iliac crest bone marrow aspiration (a), 50 to 60 mL of bone marrow aspirated (b), Bone marrow derived stem cell con-
centrated (after centrifugation) (c)
a b c
In the SG, a mean of 75 mg of methylprednisolone (45 mg to 120 
mg) was injected. At the 24 months follow up, in this group, 12 
patients were graded as failures (4 stage 1 and 8 stage 2) (Figure 2), 
while 17 patients achieved bone cyst resolutions (12 stage 3 and 5 
stage 4) (Figure 3). In this group, the overall failure rate was 41.4% 
(stage 1 and 2) and the success rate was 58.6% (stage 3 and 4). In 
the EDDBM+BMC Group, 4 patients were graded as failures (1 
stage 1 and 3 stage 2) (Figure 4), while 20 patients achieved success 
(12 stage 3 and 8 stage 4) (Figure 5).This group presented a global 
failure rate of 16.7% and a success rate of 83.3%.
The healing rate inthe EDDBM+BMC Group, therefore, was sig-
nificantly higher than the healing rate of SG (83.3% vs 58.6%; 
p=0.047).
Furthermore, female patients in both groups showed a better re-
sponse to treatment (p=0.002). 
No association was found between success rate and age (p=0.839), 
cyst activity (p=0.599), location of the cysts (p=0.099), and clinical 
presentation (p=0.207). 
Mean healing time in the SG was 17.1 months while in the EDDB-
M+BMC Group it was 15.9 months (p=0.791).
Mean ASK scores at the last follow up was 86.10±6.17 for the SG 
and 91.92±5.40 for the EDDBM+BMC Group (p=0.0007) (Dia-
gram 1, Table 3).
In the SG we reported two cases (1 male, 1 female) of persistent 
pain in the steroid injection site and treated it with oral painkillers. 
In the EDDBM+BMC Group, we reported one case of superficial 
skin infection at the iliac wing site of BMC harvesting, which was 
treated with oral antibiotics. In one patient, persistent pain at the 
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Table 2. Population data
N°
Cohort 
53
Steroid 
Group 29
EDDBM+BMC 
Group 24 p
Mean age 10.6±1.53 10.7 ±1.60 10.5 ±1.47 0.599
Sex distribution
Males 16 8 8 0.659
Females 37 21 16
Location of the cyst
Femur 13 8 5
Humerus 34 17 17 0.357
Others 6 4 2
Clinical presentation 
Pain 12 6 6
Incidental 
finding
5 2 3 0.409
Previous 
fracture
36 21 15
Active cysts 16 10 6 0.686
EDDBM: Equine Derived Demineralized Bone Matrix; BMC: Bone 
Marrow Concentrate
Figure 2. a-d. Proximal humeral cyst treated with methylprednisolone injections; pre-operative (a, c) and post-operative (b, d) x-rays 
(success)
a b c
d
EDDBM+BMC injection site was reported and treated with oral 
painkillers.
In our cohort, no patient reported refracture after treatment at the 
24-month follow up.
Discussion
The indication to treat SBC is to prevent a pathologic fracture and 
reinforcing the bone cortex. Injection strategies, decompression 
techniques, curettage or resection, with or without bone grafting, 
and combined surgical approaches were proposed to treat SBCs, 
but no method has shown striking results (33).
Surgical curettage and cyst excision with bone graft were consid-
ered as the treatment of choice to treat SBCs, but these approaches 
lost popularity because of the high risk of complications and inva-
siveness (34, 35).
Steroids, bone matrix, and BM were described as less invasive in-
jectable treatments and gained popularity (20, 21, 36-40).
It must be reported that not all SBCs can cause a pathological frac-
ture and not all SBCs need treatment. Some of them can be ob-
served without any specific treatment. In patients with impending 
or pathological fracture, intralesional injections, however, repre-
sent a valid surgical treatment option (41).
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Figure 3. a-d. Diaphyseal humeral cyst treated with methylprednisolone injections; pre-operative (a, c) and post-operative (b, d) x-rays 
(failure)
a b c
d
Figure 4. a-d. Diaphyseal femoral cyst treated with EDDBM+BMC injections; pre-operative (a, b) and post-operative x-rays (c, b) 
(success)
a b c d
Intra-cystic steroid injections with methylprednisolone was first-
ly described by Scaglietti with positive results in 90% of patients 
(13). Methylprednisolone should reduce the production of cyst 
fluid through the long-acting anti-inflammatory properties of its 
microcrystalline composition on the inner cysts membrane, which 
should facilitate the healing process (38). Further studies did not 
replicate these results, with a recurrence rate ranging from 15% to 
88% after three injection procedures (13, 42).
Autologous BM injections were also described for the treatment 
of osteolytic lesions (20-23). The rationale is that BM is the main 
source of mesenchymal stem cells (MSCs), which can differenti-
ate in a variety of cellular lineages such as cartilage, bone, tendon, 
and muscle (43-45). They also secrete cytokines that regulate local 
immune activities, playing a crucial role in bone regeneration (43-
45).
Lokiec et al., followed by Delloye et al., firstly described using au-
tologous native BM injections in the treatment of SBCs, reporting 
success in 100% of patients; however, these results were not con-
firmed in further studies (22, 23).
Some authors compared BM injections with steroids injections re-
porting a higher healing rate (52% vs 23%) and low recurrence rate 
(13% vs 42%) (17) but other studies did not confirm the superior-
ity of this treatment compared to steroids injections (21, 40, 46).
Rougraff and Kling reported the results of the association of BM 
with DBM, obtaining better results regarding a higher healing rate 
(58% vs 21%) and lower failure rate (24% vs 63%) compared to 
steroids injections (25).
Urist et al. first identified osteoconductive and oteoinductive 
properties of DBM (47). It acts as a scaffold for the deposition of 
new bone, providing also mechanical support during remodeling 
phases. DBM contains bone morphogenetic proteins; they are 
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Figure 5. a-d. Proximal humeral cyst successfully treated with EDDBM+BMC injections; pre-operative (a, c) and post-operative (b, d) 
x-rays (failure)
a b c
d
Table 3.Success rate and ASK scores in the two study groups
Steroid Group EDDBM+BMC p
Healing rate 58.60% 83.30% 0.047
ASK score 86.1±6.17 91.9±5.40 0.0007
EDDBM: Equine Derived Demineralized Bone Matrix; BMC: Bone 
Marrow Concentrate
Diagram 1. Patient distribution according to Neer-Cole’s stages
growth factors that enhance cartilage and bone formation belong-
ing to the TGF-β family (48). Using DBM is not limited by graft 
material availability and harvest morbidity and, therefore, is unin-
fluenced by donor condition (49-51).
Di Bella et al. retrospectively reviewed the results of the treatment 
of SBCs with bone marrow aspirate concentrate (BMC) injections 
in association with DBM in the treatment of simple bony cysts and 
compared them with steroids injections (26). They concentrat-
ed BM aspirate through centrifugation. It is one of the strategies 
widely available to improve the recovery of MSCs from BM aspi-
rate, enhancing their osteogenic activity, as it does not require cell 
culture ex vivo. Cell culture could expose them to immunogenicity 
and genetic stability modifications (52).
In their study, patients who underwent this treatment reported a 
healing rate of 71%, compared to 38% of those treated with meth-
ylprednisolone injections at the two-year follow up. These results 
were obtained with a significant lower number of infiltration pro-
cedures needed.
In our study, we report a better healing rate of 83.3% and a failure 
rate of 16.7%, compared to 58.6% of healing and 41.4% of failure 
reached by patients treated with methylprednisolone. The ASK 
score of our patients showed better results in patients treated with 
BMC (p=0.0007). This is could be related to the lower number of 
infiltrations, and consequently, hospitalization reported in our 
study. Fewer hospitalizations mean fewer surgeries and lower costs 
for the healthcare system.
In the SG we delivered 3mg/mL of methylprednisolone acetate ac-
cording to the cyst volume, while Di Bella et al. delivered 80mg 
of methylprednisolone acetate, not considering the cyst volume, 
potentially underestimating or overestimating the results (26). 
Furthermore, they aspirated 18 to 20 mL of bone marrow and cen-
trifuged it twice to obtain 9 to 10 mL of BMC. Fifty to 60 mL of 
bone marrow were aspirated and were once centrifuged to obtain 
10 mL of BMC, thus making our procedure more efficient regard-
ing a higher concentration of progenitor cells and cytokines with a 
single centrifugation process.
Although, currently, there is no clear consensus about the opti-
mal dose of MSCs that is considered therapeutic. Some studies 
demonstrate that higher doses provide better clinical outcomes 
(53, 54). The kit we used (IOR-G1 + ResQ 60, Novagenit, Italy) 
allows mononucleated cells (MNC) recovering more than 90%, 
platelet concentration of four-fold and red blood cells depletion 
of >96%, maintaining in the final product the key mesenchymal 
population(CD45-/CD44+/CD73+/CD90+/CD105+).
Autologous cancellous bone is considered the gold standard for 
bone defect repair (55) but its use is limited by increased opera-
tive time and donor site morbidity (56, 57). On the other hand, 
the main problems with using allografts are limited donor sources, 
high cost, higher resorption rate, and greater immunogenic re-
sponses (58). The search for alternative bone sources, therefore, 
has led to a growing interest in xenogeneic bone substitutes of an-
imal origin. They could represent a theoretically unlimited supply 
of grafting material associated with lower infection risk and lower 
costs. 
In our study, we used EDDBM, which underwent an enzymatic 
deantigenation process. Its use has shown good outcomes and 
could be considered a safe alternative to bovine-derived DBM re-
garding spongiform encephalopathy transmission risk (59-62).
EDDBM+BMC injection is a more invasive procedure compared 
to steroid injections; however, through this procedure, we obtained 
better results with just one injection compared to three steroid in-
jections. The overall hospitalization cost of a cycle (1 injection) of 
EDDBM with BMC injection was about 2700€ while the hospital-
ization cost for a cycle of three steroid injections is about 6000€ 
(2000€ for each steroid injection).
This means that we had better results with lower costs of hospi-
talization since each injection procedure both for steroids and 
EDDBM+BMC is performed in a hospitalization setting. 
We found that in 16 patients, the treatments were regarded as a 
failure but we have a few elements to draw any conclusion about 
that since the low numerosity of the cohort population, could lead 
to further bias. Pretell-Mazzini et al. consider patient age as an im-
portant factor affecting the treatment outcome (41). Patients older 
than 10 years heal at a higher rate (90%) than younger patients 
(60%), irrespective of the treatment modality. On the other hand, 
Haidar and colleagues consider a lesion located <2 cm from the 
physis as a risk factor for recurrence. The risk of recurrence could 
also be related to the type of treatment rather than the location of 
the lesion.
There is no evidence in the literature that one treatment gives bet-
ter results according to gender distribution over another. We con-
sider the better results obtained in female patients in our cohort 
as incidental.
The major limitation of the study is that the effect of EDDBM on 
the success rate is unknown. Of course, a study comparing steroid 
injections with BMC and BMC+EDDBM would be useful to better 
clarify this aspect.
This study is also limited by the retrospective design, as this would 
require a prospective experimental study with the randomization 
of patients within groups: by the small groups’ size, which have 
limited the study power, and by the lack of a long-term follow up 
that does not allow to estimate the recurrence rate after that peri-
od.
Currently, 14 different kinds of systems allowing BM aspiration 
and concentration are commercially available. The MSCs obtained 
with these systems, as they do not derive from cell culture in vivo, 
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do not meet the International Society for Cellular & Gene Therapy 
standard criteria to define properly MSCs (63). This makes it diffi-
cult to compare it with other studies, owing to the great variety in 
reported methods and outcomes.
To our knowledge, this study is the first about using EDDBM+B-
MC for the treatment of SBCs. It showed a higher healing rate and 
higher functional outcomes at two years follow up compared to 
methylprednisolone injections. It represents an effective and safe 
treatment option for orthopedic surgeons. More powered studies 
with longer follow-ups and larger samples are needed to confirm 
these results.
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